Recent News

• 07.02.2025 - Preliminary Safety and Efficacy of Givastomig, a Novel Claudin 18.2/4-1BB Bispecific Antibody, in Combination with Nivolumab and mFOLFOX in Metastatic Gastroesophageal Carcinoma (mGEC)
• 07.02.2025 - Preliminary Safety and Efficacy of Givastomig, a Novel Claudin 18.2/4-1BB Bispecific Antibody, in Combination with Nivolumab and mFOLFOX in Metastatic Gastroesophageal Carcinoma (mGEC)
• 06.17.2025 - H.C. Wainwright “HCW@Home with I-Mab”
• 06.17.2025 - H.C. Wainwright “HCW@Home with I-Mab”
• 06.12.2025 - I-Mab Regains Compliance with Nasdaq Minimum Bid Price Requirement
• 06.05.2025 - Jefferies Global Healthcare Conference
• 06.05.2025 - Jefferies Global Healthcare Conference
• 06.05.2025 - Jefferies Global Healthcare Conference
• 06.05.2025 - Jefferies Global Healthcare Conference
• 06.03.2025 - Sean Cao, PhD

Recent Filings

• 06.12.2025 - EX-99.1 EX-99.1
• 06.12.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.02.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.02.2025 - EX-99.1 EX-99.1
• 05.30.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]